“This first close of our Series A furthers our mission of bringing potentially life-saving treatments to patients in need.” –
The latest news and updates from Adze Biotech.
Adze Biotechnology Announces Orphan Drug Designation Granted to Adze-1.17-CD40L for the treatment of Malignant Glioma
CORAL GABLES, FLORIDA, UNITED STATES, February 7, 2023 Adze-1.17-CD40L is a systemically deliverable, conditionally replicative oncolytic virus that delivers recombinent
CORAL GABLES, FLORIDA, UNITED STATES, February 1, 2023. The grant of this patent positions Adze to participate in the $18